These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 9413946)
1. Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Philpott M; Joseph WR; Crosier KE; Baguley BC; Ching LM Br J Cancer; 1997; 76(12):1586-91. PubMed ID: 9413946 [TBL] [Abstract][Full Text] [Related]
2. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor. Philpott M; Ching LM; Baguley BC Eur J Cancer; 2001 Oct; 37(15):1930-7. PubMed ID: 11576850 [TBL] [Abstract][Full Text] [Related]
3. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649 [TBL] [Abstract][Full Text] [Related]
4. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211 [TBL] [Abstract][Full Text] [Related]
5. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid. Browne WL; Wilson WR; Baguley BC; Ching LM Anticancer Res; 1998; 18(6A):4409-13. PubMed ID: 9891501 [TBL] [Abstract][Full Text] [Related]
6. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Zhou S; Kestell P; Baguley BC; Paxton JW Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development. Phillips RM Biochem Pharmacol; 1999 Jul; 58(2):303-10. PubMed ID: 10423172 [TBL] [Abstract][Full Text] [Related]
8. Induction of STAT and NFkappaB activation by the antitumor agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line. Ching LM; Young HA; Eberly K; Yu CR Biochem Pharmacol; 1999 Oct; 58(7):1173-81. PubMed ID: 10484075 [TBL] [Abstract][Full Text] [Related]
9. Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Ching LM; Joseph WR; Crosier KE; Baguley BC Cancer Res; 1994 Feb; 54(4):870-2. PubMed ID: 8313372 [TBL] [Abstract][Full Text] [Related]
10. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Ching LM; Goldsmith D; Joseph WR; Körner H; Sedgwick JD; Baguley BC Cancer Res; 1999 Jul; 59(14):3304-7. PubMed ID: 10416582 [TBL] [Abstract][Full Text] [Related]
11. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Philpott M; Baguley BC; Ching LM Cancer Chemother Pharmacol; 1995; 36(2):143-8. PubMed ID: 7767951 [TBL] [Abstract][Full Text] [Related]
12. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Zhao L; Kestell P; Philpott M; Ching LM; Zhuang L; Baguley BC Cancer Chemother Pharmacol; 2001 Jun; 47(6):491-7. PubMed ID: 11459201 [TBL] [Abstract][Full Text] [Related]
13. The effect of 5,6-dimethylxanthenone-4-acetic acid on tumour necrosis factor production by human immune cells. Patel S; Parkin SM; Bibby MC Anticancer Res; 1997; 17(1A):141-50. PubMed ID: 9066644 [TBL] [Abstract][Full Text] [Related]
14. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cao Z; Baguley BC; Ching LM Cancer Res; 2001 Feb; 61(4):1517-21. PubMed ID: 11245459 [TBL] [Abstract][Full Text] [Related]
15. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Baguley BC; Zhuang L; Kestell P Oncol Res; 1997; 9(2):55-60. PubMed ID: 9167186 [TBL] [Abstract][Full Text] [Related]
16. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity. Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD Br J Cancer; 1998 Aug; 78(3):336-43. PubMed ID: 9703279 [TBL] [Abstract][Full Text] [Related]
17. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Cliffe S; Taylor ML; Rutland M; Baguley BC; Hill RP; Wilson WR Int J Radiat Oncol Biol Phys; 1994 May; 29(2):373-7. PubMed ID: 8195036 [TBL] [Abstract][Full Text] [Related]
18. NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Woon ST; Zwain S; Schooltink MA; Newth AL; Baguley BC; Ching LM Eur J Cancer; 2003 May; 39(8):1176-83. PubMed ID: 12736120 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors. Wang LC; Woon ST; Baguley BC; Ching LM Oncol Res; 2006; 16(1):1-14. PubMed ID: 16783963 [TBL] [Abstract][Full Text] [Related]
20. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice. Zhao L; Kestell P; Ching LM; Baguley BC Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]